换一批
换一批Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
作者：
主题词
腺癌(Adenocarcinoma);成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);胆管肿瘤(Bile Duct Neoplasms);胆管, 肝外(Bile Ducts, Extrahepatic);胆管, 肝内(Bile Ducts, Intrahepatic);胆道肿瘤(Biliary Tract Neoplasms);胆管上皮癌(Cholangiocarcinoma);脱氧胞苷(Deoxycytidine);无病生存(Disease-Free Survival);女(雌)性(Female);胆囊肿瘤(Gallbladder Neoplasms);人类(Humans);男(雄)性(Male);中年人(Middle Aged);有机铂化合物(Organoplatinum Compounds);预后(Prognosis);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));治疗结果(Treatment Outcome)
DOI
10.1002/cncr.29778
PMID
26540314
发布时间
2022-12-07
- 浏览51
Cancer
574-81页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
